|

Oral Carnitine in Heart Failure Patients

RECRUITINGEarly 1Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Actively Recruiting
PhaseEarly 1
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Started2025-11-12
Est. completion2026-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07201714

Summary

Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
* Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
* Age ≥ 18 years
* Able to speak and read English
* Willing and able to provide consent

Exclusion Criteria:

* Estimated GFR \<15 mL/min/1.73m2 or Stage 5 chronic kidney disease
* Currently undergoing renal replacement therapy of any kind
* Pregnant, breastfeeding or intending pregnancy
* History of seizures of any type
* Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone
* Unable to provide consent

Conditions3

Carnitine DeficiencyHeart DiseaseHeart Failure

Interventions1

Levocarnitine

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.